Pharmaceutical opioid poisonings in Victoria, Australia: Rates and characteristics of a decade of emergency department presentations among nine pharmaceutical opioids.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
03 2022
Historique:
received: 04 02 2021
accepted: 21 07 2021
pubmed: 3 8 2021
medline: 16 4 2022
entrez: 2 8 2021
Statut: ppublish

Résumé

Pharmaceutical opioids are a significant contributor to the global 'opioid crisis', yet few studies have comprehensively distinguished between opioid types. We measured whether a range of common pharmaceutical opioids varied in their contribution to the rates and characteristics of harm in a population-wide indicator of non-fatal overdose. Retrospective observational study of emergency department (ED) patient care records in the Victorian Emergency Minimum Data set (VEMD), July 2009 to June 2019. Victoria, Australia. ED presentations for non-fatal overdose related to pharmaceutical opioid use (n = 5403), where the specific pharmaceutical opioid was documented. We compared harms across the nine individual pharmaceutical opioids most commonly sold, and considered where multiple opioids contributed to the overdose. We calculated supply-adjusted rates of ED presentations using Poisson regression and used multinomial logistic regression to compare demographic and clinical characteristics of presentations among nine distinct pharmaceutical opioids and a 10th category where multiple opioids were documented for the presentation. There were wide differences, up to 27-fold, between supply-adjusted rates of overdose. When considering presentations with sole opioids, the highest supply-adjusted overdose rates [per 100 000 oral morphine equivalents (OME); 95% confidence interval (CI)] were for codeine (OME = 0.078, 95% CI = 0.073-0.08) and oxycodone (OME =0.029, 95% CI = 0.027-0.030) and the lowest were for tapentadol (OME = 0.004, 95% CI = 0.003-0.006) and fentanyl (OME = 0.003, 95% CI = 0.002-0.004). These rates appeared related to availability rather than opioid potency. Most (62%) poisonings involved females. Codeine, oxycodone and tramadol were associated with younger presentations (respectively, 59.5%, 41.7% and 49.8% of presentations were 12-34 years old), and intentional self-harm (respectively 65.2%, 50.6%, and 52.8% of presentations). Relative to morphine, fentanyl [ 0.32 relative risk ratio (RRR)] and methadone ( 0.58 RRR) presentations were less likely to be coded as self-harm. Relative to morphine-buprenorphine, codeine, oxycodone and tramadol presentations were significantly more likely to be associated with the less urgent triage categories (respectively 2.18, 1.80, 1.52, 1.65 RRR). In Victoria, Australia, rates and characteristics of emergency department presentations for pharmaceutical opioids show distinct variations by opioid type.

Sections du résumé

BACKGROUND AND AIMS
Pharmaceutical opioids are a significant contributor to the global 'opioid crisis', yet few studies have comprehensively distinguished between opioid types. We measured whether a range of common pharmaceutical opioids varied in their contribution to the rates and characteristics of harm in a population-wide indicator of non-fatal overdose.
DESIGN
Retrospective observational study of emergency department (ED) patient care records in the Victorian Emergency Minimum Data set (VEMD), July 2009 to June 2019.
SETTING
Victoria, Australia.
CASES
ED presentations for non-fatal overdose related to pharmaceutical opioid use (n = 5403), where the specific pharmaceutical opioid was documented.
MEASUREMENTS
We compared harms across the nine individual pharmaceutical opioids most commonly sold, and considered where multiple opioids contributed to the overdose. We calculated supply-adjusted rates of ED presentations using Poisson regression and used multinomial logistic regression to compare demographic and clinical characteristics of presentations among nine distinct pharmaceutical opioids and a 10th category where multiple opioids were documented for the presentation.
FINDINGS
There were wide differences, up to 27-fold, between supply-adjusted rates of overdose. When considering presentations with sole opioids, the highest supply-adjusted overdose rates [per 100 000 oral morphine equivalents (OME); 95% confidence interval (CI)] were for codeine (OME = 0.078, 95% CI = 0.073-0.08) and oxycodone (OME =0.029, 95% CI = 0.027-0.030) and the lowest were for tapentadol (OME = 0.004, 95% CI = 0.003-0.006) and fentanyl (OME = 0.003, 95% CI = 0.002-0.004). These rates appeared related to availability rather than opioid potency. Most (62%) poisonings involved females. Codeine, oxycodone and tramadol were associated with younger presentations (respectively, 59.5%, 41.7% and 49.8% of presentations were 12-34 years old), and intentional self-harm (respectively 65.2%, 50.6%, and 52.8% of presentations). Relative to morphine, fentanyl [ 0.32 relative risk ratio (RRR)] and methadone ( 0.58 RRR) presentations were less likely to be coded as self-harm. Relative to morphine-buprenorphine, codeine, oxycodone and tramadol presentations were significantly more likely to be associated with the less urgent triage categories (respectively 2.18, 1.80, 1.52, 1.65 RRR).
CONCLUSIONS
In Victoria, Australia, rates and characteristics of emergency department presentations for pharmaceutical opioids show distinct variations by opioid type.

Identifiants

pubmed: 34338377
doi: 10.1111/add.15653
pmc: PMC9292229
doi:

Substances chimiques

Analgesics, Opioid 0
Pharmaceutical Preparations 0
Tramadol 39J1LGJ30J
Morphine 76I7G6D29C
Oxycodone CD35PMG570
Fentanyl UF599785JZ
Codeine UX6OWY2V7J

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

623-636

Informations de copyright

© 2021 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.

Références

Addiction. 2016 Oct;111(10):1848-53
pubmed: 27177599
Aust Prescr. 2018 Feb;41(1):2-3
pubmed: 29507450
BMJ Open. 2020 Sep 29;10(9):e038979
pubmed: 32994254
BMC Med Res Methodol. 2002 Jun 17;2:8
pubmed: 12069695
PLoS One. 2020 Jan 17;15(1):e0227966
pubmed: 31951640
MMWR Morb Mortal Wkly Rep. 2018 Mar 09;67(9):279-285
pubmed: 29518069
Addiction. 2020 Jun;115(6):1075-1087
pubmed: 31742765
Drug Alcohol Depend. 2016 May 1;162:51-5
pubmed: 26993373
Med J Aust. 2020 Aug;213(3):142-142.e1
pubmed: 32438516
Drug Alcohol Depend. 2017 Oct 1;179:291-298
pubmed: 28826104
Drug Alcohol Rev. 2018 Nov;37(7):847-850
pubmed: 30289187
Drug Saf. 2018 Aug;41(8):787-795
pubmed: 29582394
NCHS Data Brief. 2020 Jan;(356):1-8
pubmed: 32487285
Pharmacoepidemiol Drug Saf. 2016 Jun;25(6):733-7
pubmed: 26693665
Ann Intern Med. 2018 Jun 5;168(11):783-790
pubmed: 29801093
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358
pubmed: 29596405
Addiction. 2020 Feb;115(2):261-269
pubmed: 31465131
Am J Drug Alcohol Abuse. 2016 Sep;42(5):550-555
pubmed: 27398815
JAMA Netw Open. 2019 Feb 1;2(2):e187621
pubmed: 30707224
Int J Drug Policy. 2019 Dec;74:274-284
pubmed: 31471008
Soc Psychiatry Psychiatr Epidemiol. 2008 Aug;43(8):642-52
pubmed: 18511993
BMC Emerg Med. 2016 Feb 08;16:11
pubmed: 26856978
Emerg Med J. 2004 Jan;21(1):35-8
pubmed: 14734371
Addiction. 2022 Mar;117(3):623-636
pubmed: 34338377
Acad Emerg Med. 2017 Apr;24(4):475-483
pubmed: 27763703
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Int J Drug Policy. 2020 Feb;76:102640
pubmed: 31931438
Ther Adv Drug Saf. 2018 Apr;9(4):197-205
pubmed: 29623185
Med J Aust. 2020 Apr;212(7):328
pubmed: 31709546
Drug Alcohol Rev. 2009 Jul;28(4):347-52
pubmed: 19594787

Auteurs

Tina Lam (T)

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.

Jane Hayman (J)

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.
Victorian Injury Surveillance Unit, Monash University Accident Research Centre, Monash University, Clayton, VIC, Australia.

Janneke Berecki-Gisolf (J)

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.
Victorian Injury Surveillance Unit, Monash University Accident Research Centre, Monash University, Clayton, VIC, Australia.

Paul Sanfilippo (P)

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.
Turning Point, Eastern Health, Richmond, VIC, Australia.

Dan I Lubman (DI)

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.
Turning Point, Eastern Health, Richmond, VIC, Australia.

Suzanne Nielsen (S)

Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Frankston, VIC, Australia.
Turning Point, Eastern Health, Richmond, VIC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH